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Phaeochromocytoma is a neuro-endrocrine tumour (NET) which presents multidimensional challenges during surgical 
resection in spite of our improved understanding of 
its physiological and clinical behaviour. The most 
common manifestations of this clinical condition 
include hypertension, headaches, palpitations, 
diaphoresis (episodic sweating) and feelings of doom. 
The incidence of phaeochromocytoma in the general 
population is 1–8/1,000,000.1 The triad of headaches, 
diaphoresis and palpitations is found in 20–40% of 
patients while 13% remain asymptomatic with high 
levels of catecholamines due to the downregulation 
of receptors.1 Five types of genes are known to be 
important in hereditary phaeochromocytomas and 
paragangliomas; these are found in 25% of patients 
with phaeochromocytoma [Table 1]. Genes encoding 
succinate dehydrogenase subunits D (SDHD) and B 
(SDHB) are found to be implicated in familial non-
syndromic phaeochromocytomas.1,2
Departments of 1Anaesthesia & Intensive Care and 3Medicine, Sultan Qaboos University Hospital; 2Department of Medicine, College of Medicine & Health 
Sciences, Sultan Qaboos University, Muscat, Oman
*Corresponding Author e-mail: sanathkumarbs@yahoo.com 
معاجلة ناجحة لورم القوامت باستخدام دواء البيتالول عن طريق الفم قبل العملية 
واستخدام كربيتات املغنيسيوم بالتسريب أثناء العملية اجلراحية
تقرير أربعة حاالت
 �صاناث كومار٬ روهيت ديت٬ نيكول�س ودهاو�س٬ اأميمه ال�صافعي٬ كارن نولني
abstract: Phaeochromocytoma is a rare neuroendocrine catecholamine-secreting tumour. This type of 
tumour poses multidimensional anaesthetic challenges as it has an unpredictable clinical course during surgical 
resection. The alpha-blocking agent phenoxybenzamine remained the mainstay in preoperative preparation before 
the introduction of beta-blocking agents. We report four cases operated between 2009–2012 at Sultan Qaboos 
University Hospital, Muscat, Oman. The cases were prepared with oral labetalol, as the alpha-blocking drug 
phenoxybenzamine was not immediately available. Responses to simulated stress were tested in the theatre before 
surgery. Anaesthesia was induced under invasive arterial pressure monitoring and magnesium sulphate infusion. 
Rare intraoperative surges in blood pressure during tumour manipulation were treated with sodium nitroprusside 
infusions and phentolamine boluses. All of the patients had an uneventful postoperative recovery. Preoperative 
treatment with labetalol has rarely been reported and can be considered as a potential therapeutic option with 
optimal patient monitoring if phenoxybenzamine is unavailable.
Keywords: Pheochromocytoma; Labetalol; Phenoxybenzamine; Phentolamine; Magnesium Sulfate; Intraoperative 
Care; Case Report; Oman.
امللخ�ص: ورم القوامت يف الغدة الكظرية حالة نادرة ت�صبب ارتفاع هرمون الأدرنالني. هذا النوع من الورم يفر�س حتديات متعددةعند عملية التخدير لأنه 
يوؤدي اإىل ارتفاع حاد يف �صغط الدم و م�صاعفات �رشيرية ل ميكن التنبوؤ بها اأثناءال�صتئ�صال اجلراحي. تبقى عقارات حا�رشات الألفا: فينوك�صي بنزامني 
العماد الول يف ال�صيطرة على ارتفاع �صغط الدم و التح�صري ملا قبل اجلراحة قبل ظهور عقارات حا�رشات البيتا. يف هذا التقرير ن�صتعر�س اأربع حالت 
اأجريت لهم عمليات جراحية بني 2012-2009 يف م�صت�صفى جامعة ال�صلطان قابو�س ، م�صقط، �صلطنة عمان. مت التح�صري لهذه احلالت باإعطاء لبيتالول 
عن طريق الفم لأن عقار فينوك�صي بنزامني مل يكن متوفرا يف الوقت املنا�صب. مت اختبار ال�صتجابه للإجهاد امل�صتحث يف غرفة العمليات قبل اجلراحة. مت 
التخدير حتت  مراقبة ال�صغط ال�رشياين داخل ال�رشايني مع ت�رشيب كربيتات املغني�صيوم. ارتفاعات �صغط الدم نادرة اأثناء عمليه ا�صتئ�صال الورم وقد مت 
علجها بت�رشيب مادة �صوديوم نيرتوبرو�صيد وعقار فنتول امني. وقد تعافى جميع املر�صى املذكورين بدون م�صاعفات بعد العمليات التي اأجريت لهم. 
نادرا مامت الإبلغ عن ا�صتخدام علج لبيتالول  قبل اجلراحة وميكن اعتباره خيارا علجيا حمتمل يف ظل عدم توافر عقار فينوك�صي بنزامني حتت املراقبة 
الطبية الأمثل للمري�س. 
مفتاح الكلمات: ورم القوامت؛ لبيتالول؛ فينوك�صي بنزامني؛ فينتولمني؛ كربيتات املغني�صيوم؛ رعاية جراحة داخلية؛ تقارير حالت؛ عمان.
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Different drugs and anaesthetic techniques are 
used for the perioperative management of patients with 
phaeochromocytoma.3–5 Although α-adrenoceptor 
antagonists are the mainstay of perioperative blood 
pressure control, the use of various combinations of α- 
and β-adrenoceptor antagonists has been reported.3–5 
Pretreatment with oral labetalol, as used in these cases, 
has rarely been reported, whereas intravenous labetalol 
and magnesium sulphate have been used for the rapid 
preparation of a patient with a phaeochromocytoma.6 
The following four cases highlight the possibility of 
using oral labetalol for preoperative management. 
The findings indicate that labetalol may be used in the 
preoperative management of phaeochromocytoma as 
a therapeutic option, especially if phenoxybenzamine 
is not available.
Two of the four cases of phaeochromocytoma 
were siblings. One of the siblings presented with 
severe episodic hypertension (Case 1) and the other 
with postural hypotension after standing for 30 
minutes (Case 2). However, when the latter was 
subjected to simulated stressful conditions in the 
anaesthesia induction room, he developed severe 
tachycardia and hypertension. The other two patients 
had long-established histories of serious classical 
phaeochromocytoma symptoms (Cases 3 and 4). 
None of the cases had comorbidities. All underwent 
open adrenalectomies and were operated on between 
2009–2012 at Sultan Qaboos University Hospital, 
Muscat, Oman.
Case 1
A 13-year-old girl presented with a three-year history 
of headaches, sweating, palpitations and severe 
hypertension. On initial admission to a peripheral 
hospital, her blood pressure was 180/120 mmHg. 
The diagnosis of phaeochromocytoma was made 
based on a computed tomography (CT) scan of the 
abdomen, which showed bilateral adrenal masses. Her 
plasma catecholamine and chromogranin A (CGA) 
levels were high [Table 2]. The initial echocardiogram 
(ECHO) showed a systolic dysfunction with global 
hypokinaesia and an ejection fraction (EF) of 46%. 
Since phenoxybenzamine is not available in Oman, 
she was treated with oral labetalol up to 400 mg twice 
a day (BD). After six weeks, the blood pressure was 
under control, the ECHO was normal and the EF 
was  64%. The haematocrit was 31 g/dL, indicating an 
expansion of the extracellular volume. Before being 
scheduled for a bilateral adrenalectomy, she was taken 
to the induction room to undergo a simulated stress 
test while her blood pressure and heart rate were 
monitored. Her haemodynamics remained within 
normal limits at this time as well as during subsequent 
postural changes.
The night before the surgery, the patient received 
lorazepam, a fluid preloaded with Ringer’s lactate 
solution, and midazolam as premedication. Before 
inducing anaesthesia, a bolus of magnesium sulphate 
(50 mg/Kg) was given followed by a maintenance dose 
of 15 mg/Kg/hour. Under invasive arterial pressure 
monitoring, the induction was done with fentanyl, 
propofol, cisatracurium and lidocaine (1.5 mg/Kg) 
prior to intubation. During the manipulation of 
the tumour, hypertensive derangements with short 
spikes up to 200 mmHg systolic were controlled 
with an infusion of sodium nitroprusside (SNP) and 
boluses of phentolamine, a potent α-adrenoceptor 
antagonist. Under an adequate volume replacement 
and hydrocortisone supplementation, the patient 
remained haemodynamically stable after tumour 
Table 1: Genetic correlations in phaeochromocytomas
Genetic basis of phaeochromocytomas
Familial Bilateral Malignant Multiple
SDHD RET SDHB SDHD
SDHB VHL VHL SDHB
VHL SDHD VHL
RET
Frequency of susceptibility genes in patients with 
phaeochromocytoma or paraganglioma in percent
RET VHL NF1 SDH Others







RET = roto-oncogene; VHL = von Hippel-Lindau disease tumour 
suppressor gene; NF1 = neurofibromatosistype 1 tumour suppressor gene; 
SDH = succinate dehydrogenase complex with subunit genes SDHB, 
SDHC and SDHD; MAX = MYC-associated factor X gene. 
Table 2: Plasma levels of circulating catecholamine and 













1 23,670 140 266 700
2 32,048 <54 3,012 300
3 38,400 1,104 - -
4 3,294 240 64 1,233
Normal 
ranges
650–2,433 <273 <475 27–94 
NADR = noradrenaline; CGA = plasma catecholamine and 
chromogranin A.
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removal without any vasoactive drugs.
Case 2
A 16-year-old boy, the brother of the first case, 
was diagnosed with phaeochromocytoma by CT 
scan after elevated CGA levels were found during 
family screening. He had a single right adrenal 
tumour but was asymptomatic apart from attacks of 
fainting during long periods of standing. His blood 
pressure and heart rate were normal despite high 
plasma noradrenaline levels [Table 1]. The routine 
investigations, including electrocardiography (ECG) 
and ECHO, were normal. The patient’s response to 
simulated stressful conditions was cross-checked in 
the anaesthesia induction room; he developed severe 
tachycardia with 170 beats per minute and his blood 
pressure rose to 190/130 mmHg; this was associated 
with dizziness when in an upright position [Figure 
1]. As a result, the patient was treated preoperatively 
with labetalol (100 mg BD) for two weeks. After that 
time, he was exposed to simulated stress again without 
developing tachycardia or hypertension [Figure 2]. The 
preoperative preparations and induction of anaesthesia 
were performed similarly to the first case. During the 
manipulation of the tumour, the blood pressure spikes 
were controlled with infusions of SNP and boluses of 
phentolamine. After the removal of the tumour, the 
patient required a low dose of phenylephrine infusion 
for a short period.
Case 3
A 37-year-old woman presented with a three-year 
history of severe paroxysmal headaches, palpitations 
and hypertension. A CT scan of the abdomen 
showed a right adrenal tumour with elevated plasma 
catecholamine and CGA levels [Table 2]. The patient 
had been on labetalol (400 mg BD) during the previous 
month and her symptoms had mostly subsided with 
only short episodes of palpitations. The ECG and 
ECHO were normal. During the stress simulation, the 
haemodynamics parameters remained within normal 
limits with minimal postural changes and so the 
patient was admitted for an open right adrenalectomy. 
The preoperative preparations of hydration, 
anaesthesia induction and intraoperative management 
were similar to those of the previous two cases. The 
patient had more frequent hypertensive derangements 
during the tumour dissection, which were controlled 
by phentolamine boluses. She did not require any 
vasopressor support after the removal of the tumour.
Case 4
A 50-year-old woman presented with a more than 
three-year history of headaches, palpitations and 
sweating, and had a palpable painful mass in her upper 
left abdomen. The CT scan revealed an extensive 
infarction of a huge left adrenal tumour and only 
slightly increased plasma levels of noradrenaline 
[Table 2]. Although she was normotensive, a small 
dose of labetalol (25 mg BD) was given for 15 days 
prior to surgery and her symptoms subsided to 
only short episodes of palpitations. The ECG and 
ECHO were normal. During the stress simulation, 
her haemodynamics remained within normal limits 
with no postural changes. The patient was admitted 
for an open left adrenalectomy. The preoperative 
preparations and anaesthetic management were 
similar to those of the previous three cases. However, 
her blood pressure did not fluctuate much during 
the tumour dissection except for a mild hypertensive 
episode (170/90 mmHg) which was managed with a 
 
Figure 1: Marked postural fluctuations in heart rate, 
systolic blood pressure and diastolic blood pressure in 
Case 2 before starting treatment with labetalol.
SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = 
heart rate.
 
Figure 2: After two weeks on labetalol, the haemodynamic 
variables of Case 2 showed minimal postural fluctuations.
SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = 
heart rate.
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phentolamine bolus. She did not require vasopressor 
support after the removal of the tumour.
All four cases had uneventful postoperative periods 
and were extubated in the Intensive Care Unit after a 
few hours of observation.
Discussion
The problems surrounding the pre- and perioperative 
management of phaeochromocytoma have been well 
described in the literature.3,4 The main objective in 
the preoperative management of these patients is to 
control the blood pressure, heart rate and arrhythmias, 
and to allow restoration of blood volume.3,5
There is no consensus on the best pharmacological 
agent or optimal duration of therapy for the 
preparation of these patients for surgery. Traditionally, 
phenoxybenzamine, a non-selective α-adrenergic 
antagonist, has been the mainstay of perioperative 
treatment.4,6–9 The greatest advantage of using 
phenoxybenzamine is its long duration of action. 
This is due to its non-competitive irreversible 
blockade which helps to avert the effects of surges 
of catecholamine release, particularly during the 
surgical manipulation of the tumour.4,10,11 After the 
removal of the tumour, the side-effects, such as 
postural hypotension and somnolence, may continue 
into the postoperative period; additionally, patients 
may require vasopressor support.4,12 However, 
phenoxybenzamine blocks α-2-adrenoreceptors, 
which may facilitate the noradrenaline release, 
resulting in undesirable chronotropic and inotropic 
effects.12 In some cases, these have been controlled 
with adjuvant β-adrenoreceptor antagonists.4,13 The 
other disadvantages of using phenoxybenzamine are its 
other side-effects—headaches and stuffy nose—which 
have been reported to reduce patient compliance with 
the medication regime.3,4
A variety of pharmacological agents, like prazocin, 
doxazocin and calcium channel blockers, have 
also been used in the preparation of patients with 
phaeochromocytoma.3,4,6 In the current case series, 
since phenoxybenzamine was not available, labetalol 
was used which is known to combine a selective 
competitive α-1- and non-selective competitive 
β-adrenoreceptor antagonist with the ratio of 
α:β antagonism being 1:3 after oral and 1:7 after 
intravenous administration.14 Cases have been 
reported where intravenous labetalol along with 
magnesium sulphate was used for the rapid preparation 
of patients with phaeochromocytoma without 
untoward effects.7 However, there is also a report in 
the literature of one incident of cardiovascular collapse 
where intravenous labetalol was used in an emergency 
to control blood pressure in a patient with an 
undiagnosed phaeochromocytoma.15 Two additional 
reports of oral labetalol used for preoperative 
preparation have been recorded. One case displayed a 
hypertensive response while in the other report three 
patients were successfully prepared without untoward 
incidents.16–18
The administration of labetalol lowers systemic 
blood pressure by decreasing systemic vascular 
resistance due to the α-1-blockade where reflex 
tachycardia is attenuated by a simultaneous 
β-blockade.7 Continued oral labetalol medication on 
the day of surgery has one advantage—the peak action 
of the drug occurs four hours after administration, 
acts during the operation on the active site and then 
wears off at the right time. This contributes to the 
patient’s circulatory stability after the removal of the 
tumour.
Two of the four patients in the current series, who 
responded normally to the simulated stress and were 
classically hypertensive, responded well to 100–400 
mg of labetalol BD. One of the normotensive patients, 
Case 2, had high noradrenaline levels. When exposed to 
simulated stress, he responded adversely with marked 
tachycardia and hypertension. However, two weeks 
after starting labetalol, a repeated stress test showed 
great improvement in the patient. Given the history 
of this case, the authors support the recommendation 
to prepare normotensive phaeochromocytomas with 
an α-adrenergic blockade.3,19,20 Case 4, who had an 
enormous infarcted adrenal mass with only slightly 
elevated noradrenaline levels, responded normally to 
a stress test after a small dose (25 mg) of labetalol BD.
Pacak explains the wide range of clinical presen-
tations among patients with phaeochromocytoma 
as a “desensitisation” of the receptors. Therefore, 
some patients will need significant amounts of 
adrenoreceptor blockers while others may not—despite 
high-circulating catecholamine concentrations.16 From 
the first use of magnesium sulphate in the anaesthetic 
management of phaeochromocytoma, there have 
been multiple case series which have confirmed its use 
during surgery. It has also been used in three patients 
with phaeochromocytoma, all of whom presented 
with severe cardiovascular instability.21–23
In the current cases series, magnesium sulphate 
was used in all cases as it inhibits the release of 
catecholamine from the adrenal medulla and 
adrenergic nerve endings; it has direct vasodilatory 
effects and anti-arrhythmic properties.21 Since the 
patients in this series were on oral labetalol and the 
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severity of blood pressure derangements during 
surgery could not be anticipated, the potent alpha-
blocker, phentolamine, was kept available and used 
during the tumour dissection. In addition, magnesium 
sulphate infusions were used in all of the patients—
from the induction of anaesthesia until the final 
removal of the tumour. This may have contributed to 
the patients’ successful outcomes. In the postoperative 
period, especially after the removal of the tumour, 
there were no significant hypotensive episodes 
which required inotropic support. All patients were 
haemodynamically stable and extubated after a few 
hours of observation.
Conclusion
The traditional view of a preoperative stabilisation 
phase with phenoxybenzamine has stood the test of 
time. Although the use of labetalol is controversial 
as the first choice of treatment in the preparation 
of these types of patients, this pilot report of four 
cases has shown that oral labetalol, in combination 
with magnesium sulfate used intraoperatively, may 
be a potential therapeutic option in patients with 
phaeochromocytoma if phenoxybenzamine is not 
available. Despite the fact that these patients were 
exposed to simulated stress, the authors do not 
recommend this as a routine practice; the Roizen 
criteria should still be met if applicable. This case 
series encourages further study of the use of labetalol 
in order to collect and publish the necessary data and 
so establish a safe recommendation.
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